Annual Accounts Receivable
$0.00
-$39.90 K-100.00%
31 December 2023
Summary:
Inhibikase Therapeutics annual accounts receivable is currently $0.00, with the most recent change of -$39.90 thousand (-100.00%) on 31 December 2023. During the last 3 years, it has risen by $0.00 (0.00%). IKT annual accounts receivable is now -100.00% below its all-time high of $472.90 thousand, reached on 31 December 2018.IKT Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
N/A
30 September 2024
Summary:
Inhibikase Therapeutics quarterly accounts receivable is not available.IKT Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -100.0% | - |
| 3 y3 years | 0.0% | - |
| 5 y5 years | -100.0% | - |
IKT Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -100.0% | |||
| 5 y | 5 years | -100.0% | |||
| alltime | all time | -100.0% |
Inhibikase Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | - | $0.00(0.0%) |
| Dec 2023 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2023 | - | $0.00(-100.0%) |
| June 2023 | - | $79.60 K(+23.4%) |
| Mar 2023 | - | $64.50 K(+61.7%) |
| Dec 2022 | $39.90 K | $39.90 K(+189.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $13.80 K(+109.1%) |
| June 2022 | - | $6600.00(-86.3%) |
| Mar 2022 | - | $48.00 K(-56.4%) |
| Dec 2021 | $110.10 K(>+9900.0%) | $110.10 K(>+9900.0%) |
| Dec 2020 | $0.00(-100.0%) | $0.00 |
| Dec 2018 | $472.90 K | - |
FAQ
- What is Inhibikase Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual accounts receivable year-on-year change?
- What is the all time high quarterly accounts receivable for Inhibikase Therapeutics?
What is Inhibikase Therapeutics annual accounts receivable?
The current annual accounts receivable of IKT is $0.00
What is the all time high annual accounts receivable for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual accounts receivable is $472.90 K
What is Inhibikase Therapeutics annual accounts receivable year-on-year change?
Over the past year, IKT annual accounts receivable has changed by -$39.90 K (-100.00%)
What is the all time high quarterly accounts receivable for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly accounts receivable is $110.10 K